Costs Associated with Exit or Disposal Activities. On August 28, 2026, the Board of Directors (the “ Board ”) of TELA Bio, Inc. (the “ Company ”) approved a reduction in workforce (the “ Plan ”) in order to reduce the Company’s operating expenses and preserve capital to focus on improving product sales to support increasing future revenue growth. The Plan will reduce the Company’s workforce by approximately 20%, from 201 full-time employees to 160 full-time employees, and is expected to be su…

CFO — Roberto Cuca: The CFO and COO is being terminated without cause, representing a significant loss of senior management.

CEO — Antony Koblish: The CEO is departing via a separation agreement with significant severance and equity acceleration, indicating a non-routine executive exit.

Results of Operations and Financial Condition. On August 10, 2026, TELA Bio, Inc. (the “ Company ”) issued a press release announcing its financial results for the second quarter ended June 30, 2026. A copy of this press release is furnished as Exhibit 99.1 hereto. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to…

Chief Executive Officer — Antony Koblish: Mr. Koblish resigned as CEO and from the Board, with Heather Getz appointed as his successor.

The filing describes an equity plan amendment and does not involve any changes in management or executive roles.

Results of Operations and Financial Condition. On May 12, 2026, TELA Bio, Inc. (the “ Company ”) issued a press release announcing its financial results for the first quarter ended March 31, 2026. A copy of this press release is furnished as Exhibit 99.1 hereto. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to th…

Results of Operations and Financial Condition. On April 29, 2026, TELA Bio, Inc. (the “ Company ”) issued a press release announcing its preliminary unaudited revenue for the quarter ended March 31, 2026 of approximately $19.0 million. The Company has not yet completed its quarter-end close processes for the quarter ended March 31, 2026. This unaudited, preliminary amount has been prepared by and is the responsibility of management. This amount is based upon information available to managemen…

Chairman of the Board — Doug Evans: Doug Evans is retiring from the Board and will be succeeded by Joseph Capper.

Results of Operations and Financial Condition. On March 24, 2026, TELA Bio, Inc. (the “ Company ”) issued a press release announcing its financial results for the fourth quarter of 2025 and the fiscal year ended December 31, 2025. A copy of this press release is furnished as Exhibit 99.1 hereto. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On March 17, 2026, TELA Bio, Inc. (the “ Company ”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “ Staff ”) of the Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The…

Termination of a Material Definitive Agreement. In connection with the entry into the Credit Agreement, the Company’s Credit and Security Agreement, dated as of May 26, 2022, with MidCap Financial Trust (“ MidCap ”) was terminated, effective as of the Funding Date, and MidCap’s security interest in the Company’s assets and property was released.

Unregistered Sales of Equity Securities. The information set forth under Item 1.01(a) of this Current Report on Form 8-K with respect to the Warrants is incorporated by reference into this

Entry into a Material Definitive Agreement. (a) Entry into Perceptive Term Loan Facility On November 13, 2025 (the “ Signing Date ”), TELA Bio, Inc. (the “ Company ”) entered into a Credit Agreement and Guaranty (the “ Credit Agreement ”) with Perceptive Credit Holdings V, LP, as lender and administrative agent (“ Perceptive ”), which provides for a senior secured term loan facility in an aggregate principal amount of up to $70.0 million (the “ Perceptive Term Loan Facility ”). An initial loa…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under Item 1.01(a) of this Current Report on Form 8-K is incorporated by reference into this

Results of Operations and Financial Condition. On November 13, 2025, TELA Bio, Inc. (the “ Company ”) issued a press release announcing its financial results for the third quarter ended September 30, 2025. A copy of this press release is furnished as Exhibit 99.1 hereto. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subj…

Class I director — William Plovanic: Appointment of William Plovanic as a Class I director.

Director — Lisa Colleran: Ms. Colleran resigned from the Board and her positions on various committees.

Results of Operations and Financial Condition. On August 11, 2025, TELA Bio, Inc. (the “ Company ”) issued a press release announcing its financial results for the second quarter ended June 30, 2025. A copy of this press release is furnished as Exhibit 99.1 hereto. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to…

President — Jeffrey Blizard: Jeffrey Blizard resigned from the Board and was appointed as President of the Company.

The filing describes an amendment to the equity incentive plan, not a management change.

Results of Operations and Financial Condition. On May 8, 2025, TELA Bio, Inc. (the “ Company ”) issued a press release announcing its financial results for the first quarter ended March 31, 2025. A copy of this press release is furnished as Exhibit 99.1 hereto. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the…

Results of Operations and Financial Condition. On March 20, 2025, TELA Bio, Inc. (the “ Company ”) issued a press release announcing its financial results for the fourth quarter of 2024 and the fiscal year ended December 31, 2024. A copy of this press release is furnished as Exhibit 99.1 hereto. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange…

Results of Operations and Financial Condition. On November 7, 2024, TELA Bio, Inc. (the “ Company ”) issued a press release announcing its financial results for the third quarter ended September 30, 2024. A copy of this press release is furnished as Exhibit 99.1 hereto. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subje…

Entry into a Material Definitive Agreement. On October 23, 2024, TELA Bio, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) by and between Canaccord Genuity LLC, as representative of the several underwriters named therein (the “ Underwriters ”) relating to the issuance and sale of an aggregate of (i) 12,000,000 shares (the “ Firm Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), to the Underwriters at a pr…